FDA approves Pfizer's biosimilar version of Remicade: 3 things to know

The FDA approved Pfizer's biosimilar Ixifi on Wednesday.

Here are three things to know.

1. Ixifi is a biosimilar version of Johnson & Johnson's immunosuppressive drug Remicade.

2. The drug is intended to treat rheumatoid arthritis, Crohn's disease and plaque psoriasis, among other illnesses.

3. Both Ixifi and Remicade contain a boxed warning over an increased risk of serious infections and cancer.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars